Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-Analysis

Introduction Emerging epidemiological evidence suggests that proton pump inhibitor (PPI) acid-suppression therapy is associated with an increased risk of Clostridium difficile infection (CDI). Methods Ovid MEDLINE, EMBASE, ISI Web of Science, and Scopus were searched from 1990 to January 2012 for analytical studies that reported an adjusted effect estimate of the association between PPI use and CDI. We performed random-effect meta-analyses. We used the GRADE framework to interpret the findings. Results We identified 47 eligible citations (37 case-control and 14 cohort studies) with corresponding 51 effect estimates. The pooled OR was 1.65, 95% CI (1.47, 1.85), I2 = 89.9%, with evidence of publication bias suggested by a contour funnel plot. A novel regression based method was used to adjust for publication bias and resulted in an adjusted pooled OR of 1.51 (95% CI, 1.26–1.83). In a speculative analysis that assumes that this association is based on causality, and based on published baseline CDI incidence, the risk of CDI would be very low in the general population taking PPIs with an estimated NNH of 3925 at 1 year. Conclusions In this rigorously conducted systemic review and meta-analysis, we found very low quality evidence (GRADE class) for an association between PPI use and CDI that does not support a cause-effect relationship.

[1]  R. Cavallazzi,et al.  Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis , 2012, The American Journal of Gastroenterology.

[2]  D. Adler,et al.  Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis , 2012, The American Journal of Gastroenterology.

[3]  Anil K. Jain,et al.  Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  L. Køber,et al.  Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study , 2011, BMJ : British Medical Journal.

[5]  Sang Min Park,et al.  Use of Acid-Suppressive Drugs and Risk of Fracture: A Meta-analysis of Observational Studies , 2011, The Annals of Family Medicine.

[6]  Deepak L. Bhatt,et al.  Clopidogrel with or without omeprazole in coronary artery disease. , 2010, The New England journal of medicine.

[7]  J. Chenot,et al.  PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Appropriateness of treatment recommendations for PPI in hospital discharge letters , 2010 .

[8]  Michele Tarsilla Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[9]  A. Reid,et al.  Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice. , 2010, Archives of internal medicine.

[10]  M. Howell,et al.  Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. , 2010, Archives of internal medicine.

[11]  C. Teljeur,et al.  Potentially inappropriate prescribing and cost outcomes for older people: a national population study. , 2010, British journal of clinical pharmacology.

[12]  M. Loeb,et al.  Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia , 2010, Alimentary pharmacology & therapeutics.

[13]  A. Ananthakrishnan,et al.  Clostridium difficile Is Associated With Poor Outcomes in Patients With Cirrhosis: A National and Tertiary Center Perspective , 2010, The American Journal of Gastroenterology.

[14]  C. Donskey,et al.  Examination of Potential Mechanisms To Explain the Association between Proton Pump Inhibitors and Clostridium difficile Infection , 2009, Antimicrobial Agents and Chemotherapy.

[15]  Nicola J Cooper,et al.  Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications , 2009, BMJ : British Medical Journal.

[16]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[17]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[18]  R. Chinn,et al.  National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. , 2009, American journal of infection control.

[19]  S. Dial,et al.  Proton Pump Inhibitor Use and Enteric Infections , 2009, The American Journal of Gastroenterology.

[20]  Santiago G. Moreno,et al.  BMC Medical Research Methodology , 2009 .

[21]  Alex J Sutton,et al.  Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. , 2008, Journal of clinical epidemiology.

[22]  D. Altman,et al.  Assessing Risk of Bias in Included Studies , 2008 .

[23]  D. Altman,et al.  Chapter 8: Assessing risk of bias in included studies , 2008 .

[24]  C. Wilcox,et al.  Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole , 2008, BMC gastroenterology.

[25]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[26]  L. Mascola,et al.  Increase in Clostridium difficile–related Mortality Rates, United States, 1999–2004 , 2007, Emerging infectious diseases.

[27]  M. Vela,et al.  Systematic review: proton pump inhibitor‐associated acute interstitial nephritis , 2007, Alimentary pharmacology & therapeutics.

[28]  V. Debari,et al.  Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. , 2007, Annals of clinical and laboratory science.

[29]  C. Donskey,et al.  Vegetative Clostridium difficile Survives in Room Air on Moist Surfaces and in Gastric Contents with Reduced Acidity: a Potential Mechanism To Explain the Association between Proton Pump Inhibitors and C. difficile-Associated Diarrhea? , 2007, Antimicrobial Agents and Chemotherapy.

[30]  John K Marshall,et al.  Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression , 2007, The American Journal of Gastroenterology.

[31]  B. Batuwitage,et al.  Inappropriate prescribing of proton pump inhibitors in primary care , 2007, Postgraduate Medical Journal.

[32]  D. Juurlink,et al.  Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  S. Schneeweiss Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.

[34]  E. Magnani,et al.  Inadequate Use of Acid-Suppressive Therapy in Hospitalized Patients and Its Implications for General Practice , 2005, Digestive Diseases and Sciences.

[35]  H. O'connor,et al.  Proton pump inhibitors: a survey of prescribing in an Irish general hospital , 2004, International journal of clinical practice.

[36]  A. Huang,et al.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies , 2004, Canadian Medical Association Journal.

[37]  L. Archibald,et al.  Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. , 2004, The Journal of infectious diseases.

[38]  E. Björnsson,et al.  Overuse of acid suppressive therapy in hospitalised patients with pulmonary diseases. , 2003, Respiratory medicine.

[39]  Didier Pittet,et al.  Guideline for Hand Hygiene in Health-Care Settings Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC / SHEA / APIC / IDSA Hand Hygiene Task Force , 2002 .

[40]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[41]  J. Zhang,et al.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. , 1998, JAMA.

[42]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[43]  A. Blum,et al.  Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. , 1996, Gut.

[44]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[45]  K. Wilson Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination , 1983, Journal of clinical microbiology.

[46]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[47]  K. Devault,et al.  Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection , 2012 .

[48]  N. Fishman,et al.  Healthcare Infection Control Practices Advisory Committee , 2012 .

[49]  T. Einarson,et al.  Association Between Use of Proton Pump Inhibitors and a Clostridium difficile-Associated Disease Outbreak: Case-Control Study. , 2010, The Canadian journal of hospital pharmacy.

[50]  J. Peters,et al.  Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids , 2007, Journal of Gastrointestinal Surgery.

[51]  M. Owings,et al.  Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. , 2006, Emerging infectious diseases.